Next-Generation Point-of-Care Tests for Longitudinal Monitoring of Patients Treated for Human Papilloma Virus (HPV)-Driven Cancer

循环人乳头瘤病毒DNA（cHPV-DNA）作为残留疾病的生物标志物和HPV相关癌症根治治疗后的疾病监测显示出很大的前景。例如，在皇家马斯登医院的可行性研究中，已经进行了下一代测序测定以测量cHPV-DNA，其中包括患有头颈部、宫颈和肛门鳞状细胞癌的患者。然而，就所需的人员、成本和时间而言，该测定是资源密集型的。在拟议的项目中，我们将开发一种快速，具有成本效益的检测方法来测量血浆中的cHPV-DNA，并最终能够开发下一代HPV选择性即时检测。

Circulating human papilloma virus DNA (cHPV-DNA) has shown great promise as a biomarker of residual disease and for disease surveillance following radical treatment for HPV related cancers. For example in feasibility studies at The Royal Marsden Hospital, next generation sequencing assays have been performed for measuring cHPV-DNA that included patients with head and neck, cervical and anal squamous cell carcinoma. However, this assay is resource intense, in terms of personnel, cost and time required. In the proposed project we will develop a rapid, cost-effective assay to measure cHPV-DNA in plasma, and will ultimately enable the development of next-generation HPV-selective point-of-care tests.